Arterial Plaque Impacts Women Differently From Men

Why It Matters

Understanding that women suffer heart attacks with less plaque reshapes risk stratification, prompting clinicians to adopt more sensitive diagnostic criteria for female patients.

Key Takeaways

• Women develop serious cardiac events with less arterial plaque than men
• Traditional plaque‑volume thresholds may miss high‑risk women
• PROMISE trial analyzed imaging from thousands of chest‑pain patients
• Gender‑specific diagnostics could reduce missed heart‑attack diagnoses
• Personalized treatment plans needed for women’s cardiovascular health

Pulse Analysis

Cardiovascular disease has long been framed through a male‑centric lens, with most risk models built on data from men. Recent research, however, underscores that atherosclerosis behaves differently in women. Hormonal influences, vessel size, and plaque composition contribute to a distinct disease trajectory, meaning that women often present with atypical symptoms and may harbor less visible plaque yet still face high event rates. Recognizing these nuances is essential for clinicians, insurers, and policymakers aiming to close the gender gap in heart‑health outcomes.

The PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial provides robust evidence of this disparity. By enrolling over 10,000 patients and employing coronary CT angiography, researchers quantified plaque burden and correlated it with subsequent cardiac events. The data revealed that women required roughly 30% less plaque volume to experience myocardial infarction or unstable angina compared with men. This lower threshold challenges the reliance on absolute plaque measurements and suggests that imaging thresholds and scoring systems should be recalibrated for female physiology.

Looking ahead, the findings advocate for a shift toward gender‑tailored cardiovascular care. Integrating sex‑specific risk calculators, adopting advanced imaging modalities that capture plaque vulnerability, and educating providers about atypical presentations can improve early detection. Moreover, pharmaceutical trials must ensure adequate female representation to validate therapeutic efficacy across sexes. As the healthcare industry embraces precision medicine, acknowledging and acting on these gender differences will be pivotal in reducing preventable heart attacks among women.